MedTrace Logo

A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies

NCT07197554 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 171

Last updated 2026-02-18

No results posted yet for this study

Summary

A Phase 1/1B Study of ST-01156 in Patients with Advanced Solid Malignancies

Conditions

Interventions

DRUG

ST-01156

ST-01156 is an orally administered degrader of RBM39, a protein frequently upregulated in cancer

Sponsors & Collaborators

  • SEED Therapeutics, Inc.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-12-01
Primary Completion
2029-12-31
Completion
2029-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07197554 on ClinicalTrials.gov